Skip to main content

ANSIRH Update: December 2017

Research in 2017

We did not slow down on publishing our research in 2017 — we published 59 peer-reviewed research articles. Some highlights include:

Media and Op-eds in 2017

We also held strong to our commitment to disseminate our research results. Our work was featured in 223 media articles. Among those articles, 66 were written by news outlets that had not previously covered ANSIRH.

In addition to coverage of our research, my viral Twitter exchange with former Rep. Trent Franks around the 20-week abortion ban was highlighted in Teen Vogue.

We also wrote several op-eds and letters to the editor that were strategically placed with local and national media outlets, including:

Awards in 2017

ANSIRH researchers received some of our field’s most prestigious awards over the past year, including:

ANSIRH’s 15th Anniversary

Over the past year, we hosted two celebratory events to honor our research, history, staff, and supporters.

On June 8th, ANSIRH researchers and collaborators gathered for a seminar on medication abortion. We discussed the history of ANSIRH’s commitment to researching medication abortion, current restrictions on the method, options for expanding provision, legislation that would improve access, and future directions.

On October 11th, we celebrated ANSIRH’s anniversary with donors, supporters, and friends. The evening featured guest speakers Dr. Tracy Weitz, ANSIRH co-founder, and Stephanie Toti, lead litigator in the Whole Woman’s Health v. Hellerstedt case.

Looking forward to 2018

ANSIRH will continue to produce rigorous research that supports the advancement of sexual and reproductive health for many years to come, and we are well-poised to tackle the many challenges in the year ahead for our field. Here’s a peek at what we have lined up in the coming months:

  • The Turnaway Study will release the results of two analyses. The first publication, due to be released in the American Journal of Public Health in mid-January, examines the economic consequences of being able to access abortion compared to being denied a wanted abortion. The second analysis focuses on changes in alcohol, tobacco and drug use over five years among women who received abortions compared to those who did not.
  • Ibis Reproductive Health and ANSIRH will publish the results of our medication abortion harm-reduction model in Peru where we surveyed women on whether or not they had an abortion and, if they did, what their experience was.
  • Our ADAPT study will be sharing a new validated measure to prospectively assess women’s preferences around pregnancy.
  • ANSIRH is planning to test a new telemedicine-based model of providing medication abortion. The California Home Abortion by Telemedicine (CHAT) Study will be the first of its kind in the U.S. and aims to reduce barriers for people who face geographic, financial, and logistical barriers to obtaining timely abortion care as well as increase their reproductive autonomy.

Follow ANSIRH

Follow us on Twitter and Facebook for the latest news about ANSIRH!